ONC.L

Oncimmune Holdings Plc
Oncimmune Hldgs PLC - Posting of Circular and Notice of General Meeting
23rd October 2024, 15:12
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3571J
Oncimmune Holdings PLC
23 October 2024
 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Posting of Circular and Notice of General Meeting

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company providing research services to the pharmaceutical and biotechnology industry to enable the delivery of precision medicine, announces that, further to its announcement of 18 October 2024 containing details of the Fundraising and Debt Restructuring (the "Launch Announcement"), the Circular providing further details of the Fundraising and Debt Restructuring and convening the General Meeting has been posted to Shareholders today.

 

The Circular contains a notice of the General Meeting which is to be held at the offices of Cavendish Financial Plc, 1 Bartholomew Close, London EC1A 7BL, at 11:00 a.m. on 8 November 2024 to approve the resolutions required to, inter alia, implement the Fundraising and the Debt Restructuring.

 

The Circular and Form of Proxy (which will be sent to Shareholders along with the Circular) will also shortly be available on the Company's website www.oncimmune.com.

 

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Launch Announcement.

 

 

For further information:

 

Oncimmune Holdings plc

contact@oncimmune.com

 

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance) 

Nigel Birks, Life Science Specialist Sales

Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

 

Zeus (Joint Broker)

Dominic King, Dan Bate

+44 (0)20 3829 5000

 

About Oncimmune

 

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

 

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

 

For more information, visit www.oncimmune.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGPPGUGUUPCGAW]]>
TwitterFacebookLinkedIn